{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:26:29Z","timestamp":1789770389012,"version":"4.0.1"},"reference-count":125,"publisher":"Tech Science Press","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.067791","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:51:42Z","timestamp":1758271902000},"page":"3161-3183","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions"],"prefix":"10.32604","volume":"33","author":[{"given":"Matthew","family":"Rubinstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline Lauren","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi Kumar","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Thomas","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Aboaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin Mon","family":"Myat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyaw Zin","family":"Thein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s12325-022-02362-4","article-title":"Histology-agnostic drugs: a paradigm shift\u2014a narrative review","volume":"40","author":"Mansinho","year":"2023 Apr","journal-title":"Adv Ther"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.soc.2023.12.001","article-title":"Tissue-agnostic cancer therapy approvals","volume":"33","author":"Gouda","year":"2024","journal-title":"Surg Oncol Clin N Am"},{"key":"ref3","first-page":"433","article-title":"The evolving landscape of tissue-agnostic therapies in precision oncology","volume":"74","author":"Subbiah","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/EDBK_173855","article-title":"Tissue-agnostic drug development","volume":"37","author":"Flaherty","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2017-0519","article-title":"The marriage between genomics and immunotherapy: mismatch meets its match","volume":"24","author":"Subbiah","year":"2019 Jan","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"ref7","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication [Internet]. [cited 2025 Apr 6]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3390\/medicina58111572","article-title":"Dostarlimab an inhibitor of PD-1\/PD-L1: a new paradigm for the treatment of cancer","volume":"58","author":"Alkholifi","year":"2022","journal-title":"Medicina"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-030-02505-2_5","article-title":"Skin reactions to immune checkpoint inhibitors","volume":"995","author":"Patel","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40264-018-0774-8","article-title":"Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer","volume":"42","author":"Baraibar","year":"2019","journal-title":"Drug Saf"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3390\/biomedicines10040790","article-title":"Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC)-their incidence, management, multiorgan irAEs, and rechallenge","volume":"10","author":"Vaddepally","year":"2022","journal-title":"Biomedicines"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","article-title":"Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model","volume":"4","author":"Reardon","year":"2016 Feb","journal-title":"Cancer Immunol Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"20003","DOI":"10.1038\/s41598-021-99364-z","article-title":"Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors","volume":"11","author":"Shimozaki","year":"2021 Oct 8","journal-title":"Sci Rep"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2178220","DOI":"10.1080\/21645515.2023.2178220","article-title":"Dostarlimab: from preclinical investigation to drug approval and future directions","volume":"19","author":"Cicala","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e2341165","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw Open"},{"key":"ref18","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors [Internet]. [cited 2025 Apr 6]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.trecan.2022.11.003","article-title":"Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies","volume":"9","author":"Bhamidipati","year":"2023","journal-title":"Trends Cancer"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-023-01073-9","article-title":"Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms","volume":"13","author":"Wang","year":"2023","journal-title":"Cell Biosci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"887383","DOI":"10.3389\/fonc.2022.887383","article-title":"The gut microbiota modulates responses to anti-PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors","volume":"12","author":"Wu","year":"2022 Oct 25","journal-title":"Front Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e003091","DOI":"10.1136\/jitc-2021-003091","article-title":"Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors","volume":"10","author":"Cristescu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41698-024-00679-7","article-title":"Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab","volume":"8","author":"Lin","year":"2024 Sep 14","journal-title":"npj Precis Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"650491","DOI":"10.3389\/fimmu.2021.650491","article-title":"Tumor mutation burden and immune invasion characteristics in triple negative breast cancer: genome high-throughput data analysis","volume":"12","author":"Gao","year":"2021","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"672677","DOI":"10.3389\/fonc.2021.672677","article-title":"Beyond tumor mutation burden: tumor neoantigen burden as a biomarker for immunotherapy and other types of therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"ref26","unstructured":"U.S. Food and Drug Administration. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. [cited 2025 Apr 6]. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e000147","DOI":"10.1136\/jitc-2019-000147","volume":"8","author":"Merino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc2031965","article-title":"The spectrum of benefit from checkpoint blockade in hypermutated tumors","volume":"384","author":"Rousseau","year":"2021 Mar 25","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.3390\/cancers15245841","article-title":"Challenges and future directions in the management of tumor mutational burden-high (TMB-H) advanced solid malignancies","volume":"15","author":"Ahmed","year":"2023","journal-title":"Cancers"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-23-0090","article-title":"Tumor-agnostic precision medicine from the AACR GENIE database: clinical implications","volume":"29","author":"Gouda","year":"2023 Aug 1","journal-title":"Clin Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"103893","DOI":"10.1016\/j.amsu.2022.103893","article-title":"A review of NTRK fusions in cancer","volume":"79","author":"Manea","year":"2022 Sep","journal-title":"Ann Med Surg"},{"key":"ref36","unstructured":"U.S. Food and Drug Administration. FDA approves larotrectinib for solid tumors with NTRK gene fusions [Internet]; 2018. [cited 2025 Apr 6]. Available from: https:\/\/www.fda.gov\/drugs\/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions."},{"key":"ref37","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14656566.2021.1876664","article-title":"Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion","volume":"22","author":"Filippi","year":"2021 Apr","journal-title":"Expert Opin Pharmacother"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-3-319-91442-8_10","article-title":"Larotrectinib (LOXO-101)","volume":"211","author":"Berger","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"ref39","unstructured":"Bayer HealthCare Pharmaceuticals Inc. VITRAKVI\u00ae (larotrectinib) capsules, for oral use: FDA packaging insert [Internet]; 2022. [cited 2025 Apr 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/210861s010lbl.pdf."},{"key":"ref40","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018 Feb 22","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020 Apr","journal-title":"Lancet Oncol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: first global approval","volume":"79","author":"Scott","year":"2019 Feb","journal-title":"Drugs"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2023.41.16_suppl.3141","article-title":"Larotrectinib long-term efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer","volume":"41","author":"Hong","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"viii16","DOI":"10.1093\/annonc\/mdz384","article-title":"Identifying patients with NTRK fusion cancer","volume":"30","author":"Solomon","year":"2019 Oct","journal-title":"Ann Oncol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/PAI.0000000000000360","article-title":"Detecting gene rearrangements in patient populations through a 2-step diagnostic test comprised of rapid IHC enrichment followed by sensitive next-generation sequencing","volume":"25","author":"Murphy","year":"2017 Aug","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref46","unstructured":"U.S. Food and Drug Administration. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC [Internet]; 2019. [cited 2025 Apr 6]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc."},{"key":"ref47","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-20-2771","article-title":"FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors","volume":"27","author":"Marcus","year":"2021 Feb 1","journal-title":"Clin Cancer Res"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/neuonc\/noaa052","article-title":"Entrectinib, a TRK\/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein","volume":"22","author":"Fischer","year":"2020 Jun","journal-title":"Neuro Oncol"},{"key":"ref49","unstructured":"Genentech, Inc. ROZLYTREK (entrectinib) capsules, for oral use: FDA packaging insert [Internet]; 2022. [cited 2025 Apr 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/212725s011lbl.pdf."},{"key":"ref50","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3122\/jabfm.2015.01.140072","article-title":"Improvement in lung cancer outcomes with targeted therapies: an update for family physicians","volume":"28","author":"Rolfo","year":"2015 Jan\u2013Feb","journal-title":"J Am Board Fam Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022 Apr 1","journal-title":"Clin Cancer Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"10286","DOI":"10.1021\/acs.jmedchem.1c00712","article-title":"Discovery of the next-generation pan-TRK kinase inhibitors for the treatment of cancer","volume":"64","author":"Liu","year":"2021 Jul 22","journal-title":"J Med Chem"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent-front mutations","volume":"8","author":"Drilon","year":"2018 Oct","journal-title":"Cancer Discov"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon","year":"2024 Jan 11","journal-title":"N Engl J Med"},{"key":"ref55","unstructured":"Bristol Myers Squibb. AUGTYROTM (repotrectinib) capsules, for oral use: FDA packaging insert [Internet]; 2024. [cited 2025 Apr 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218213s001lbl.pdf."},{"key":"ref56","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0959-8049(22)01000-0","article-title":"Update from the ongoing phase 1\/2 registrational trial of repotrectinib: results in TKI-na\u00efve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)","volume":"174","author":"Besse","year":"2022 Oct","journal-title":"Eur J Cancer"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon","year":"2023 Sep","journal-title":"Ann Oncol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"e2200697","DOI":"10.1200\/PO.22.00697","article-title":"Response to repotrectinib after development of NTRK resistance mutations on first- and second-generation TRK inhibitors","volume":"7","author":"Chen","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"ref59","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors [Internet]; 2023. [cited 2025 Apr 6]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive."},{"key":"ref60","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.apsb.2023.11.010","article-title":"Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib","volume":"14","author":"Xiang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"864666","DOI":"10.3389\/fonc.2022.864666","article-title":"NTRK fusion in non-small cell lung cancer: diagnosis, therapy, and TRK inhibitor resistance","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-019-0542-z","article-title":"Resistance to TRK inhibition mediated by convergent MAPK pathway activation","volume":"25","author":"Cocco","year":"2019","journal-title":"Nat Med"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1535370220959657","article-title":"Prevalence of class I\u2013III BRAF mutations among 114,662 cancer patients in a large genomic database","volume":"246","author":"Owsley","year":"2021 Jan","journal-title":"Exp Biol Med"},{"key":"ref65","unstructured":"FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. [cited 2025 Apr 6]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid."},{"key":"ref66","doi-asserted-by":"crossref","first-page":"e404770","DOI":"10.1200\/EDBK_404770","article-title":"Expanding the benefit: dabrafenib\/trametinib as tissue-agnostic therapy for BRAF V600E-positive adult and pediatric solid tumors","volume":"43","author":"Gouda","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1078-0432.CCR-23-1503","article-title":"FDA approval summary: dabrafenib in combination with trametinib for BRAFV600E mutation-positive low-grade glioma","volume":"30","author":"Barbato","year":"2024","journal-title":"Clin Cancer Res"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"100788","DOI":"10.1016\/j.esmoop.2023.100788","article-title":"Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy","volume":"8","author":"Gouda","year":"2023","journal-title":"ESMO Open"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40265-018-0884-8","article-title":"BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers","volume":"78","author":"Sanchez","year":"2018","journal-title":"Drugs"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.devcel.2009.07.013","article-title":"Ret-dependent cell rearrangements in the Wolffian duct epithelium initiate ureteric bud morphogenesis","volume":"17","author":"Chi","year":"2009","journal-title":"Dev Cell"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1101\/gad.205001","article-title":"Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis","volume":"15","author":"de Graaff","year":"2001","journal-title":"Genes Dev"},{"key":"ref75","first-page":"191","article-title":"Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues","volume":"10","author":"Tsuzuki","year":"1995","journal-title":"Oncogene"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/carcin\/bgz184","article-title":"REToma: a cancer subtype with a shared driver oncogene","volume":"41","author":"Kohno","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref78","first-page":"472","article-title":"RET kinase alterations in targeted cancer therapy","volume":"3","author":"Liu","year":"2020","journal-title":"Cancer Drug Resist"},{"key":"ref79","first-page":"1170","article-title":"The ret\/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults","volume":"85","author":"Fenton","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum Mol Genet"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-art strategies for targeting RET-dependent cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","article-title":"FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions","volume":"27","author":"Bradford","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref85","unstructured":"U.S. Food and Drug Administration. FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors. [cited 2025 Apr 6]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors."},{"key":"ref86","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1158\/1078-0432.CCR-23-0459","article-title":"FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors","volume":"29","author":"Duke","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1200\/JCO.2024.42.3_suppl.746","article-title":"Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: lIBRETTO-001","volume":"42","author":"Subbiah","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1158\/1078-0432.CCR-16-1887","article-title":"Antitumor activity of RXDX-105 in multiple cancer types with RET rearrangements or mutations","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"33577","DOI":"10.1074\/jbc.M605604200","article-title":"Structure and chemical inhibition of the RET tyrosine kinase domain","volume":"281","author":"Knowles","year":"2006","journal-title":"J Biol Chem"},{"key":"ref92","unstructured":"New England Journal of Medicine Illustrated Glossary. Solvent front variant. [cited 2025 Apr 6]. Available from: https:\/\/illustrated-glossary.nejm.org\/term\/solvent_front_variant."},{"key":"ref93","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020 Apr","journal-title":"J Thorac Oncol"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"LBA3000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results","volume":"41","author":"Meric-Bernstam","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref96","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-Nxki for unresectable or metastatic HER2-positive solid tumors. [cited 2025 Apr 6]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2."},{"key":"ref97","doi-asserted-by":"crossref","first-page":"17588359231169983","DOI":"10.1177\/17588359231169983","article-title":"Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer","volume":"15","author":"Yang","year":"2023 May 21","journal-title":"Ther Adv Med Oncol"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.critrevonc.2019.05.001","article-title":"Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives","volume":"139","author":"Vernieri","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1535-6108(02)00097-1","article-title":"Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth","volume":"2","author":"Agus","year":"2002","journal-title":"Cancer Cell"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?","volume":"94","author":"Arnould","year":"2006 Jan 30","journal-title":"Br J Cancer"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022 Jan","journal-title":"Cancer Discov"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.21.02285","article-title":"Basket trials: review of current practice and innovations for future trials","volume":"40","author":"Hobbs","year":"2022 Oct 20","journal-title":"J Clin Oncol"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021 Nov 15","journal-title":"Signal Transduct Target Ther"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N Engl J Med"},{"key":"ref107","first-page":"391","article-title":"Glimmers of hope for targeting oncogenic KRAS-G12D","volume":"30","author":"Tang","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2025.0122","article-title":"Drugging the \u2018undruggable\u2019 KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer","author":"Khan","year":"2025 Jul 7","journal-title":"Cancer Biol Med"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): An international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"e2400113","DOI":"10.1200\/PO.24.00113","article-title":"Are FGFR fusions and mutations the next tumor-agnostic targets in oncology?","volume":"8","author":"Ellis","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rod\u00f3n","year":"2024","journal-title":"Nat Med"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.annonc.2020.08.2335","article-title":"NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents","volume":"31","author":"Laskin","year":"2020","journal-title":"Ann Oncol"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"key":"ref114","first-page":"125","article-title":"An overview of precision oncology basket and umbrella trials for clinicians","volume":"70","author":"Park","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref115","unstructured":"Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study. Bethesda (MD): National Library of Medicine (US). Identifier NCT04589845. [cited 2025 Jul 7]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04589845."},{"key":"ref116","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2018.12.003","article-title":"New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology","volume":"73","author":"Janiaud","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41586-020-2481-8","article-title":"The National Lung Matrix Trial of personalized therapy in lung cancer","volume":"583","author":"Middleton","year":"2020","journal-title":"Nature"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.clinthera.2020.05.010","article-title":"The evolution of masterprotocol clinical trial designs: a systematic literature review","volume":"42","author":"Meyer","year":"2020","journal-title":"Clin Ther"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1740774517725697","article-title":"Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: multi-arm, multi-stage platform, umbrella and basket protocols","volume":"14","author":"Parmar","year":"2017","journal-title":"Clin Trials"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N Engl J Med"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O\u2019Dwyer","year":"2023 Jun","journal-title":"Nat Med"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1158\/1078-0432.CCR-23-0917","article-title":"The new NCI precision medicine trials","volume":"29","author":"Harris","year":"2023 Dec 1","journal-title":"Clin Cancer Res"},{"key":"ref125","unstructured":"American Society of Clinical Oncology. TAPUR: testing the use of food and drug administration (FDA) approved drugs that target a specific abnormality in a tumor gene in people with advanced stage cancer (TAPUR). [cited 2025 Apr 6]. Available from: https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCT02693535&r=1."}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-11\/OncolRes-33-11-67791\/OncolRes-33-67791.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:22:30Z","timestamp":1763346150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n11\/64074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":125,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.067791","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}